Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P460: Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil

ECCO '19 Copenhagen

Year: 2019
Authors:

R. S. Parra*1, M. R. Feitosa1, O. Féres1, J. J. Ribeiro da Rocha1, J. M. F. Chebli2, L. Chebli2, E. R. Bertges2, T. N. F. Gomes3, O. Ambrogini Jr3, A. J. T. Alves Junior4, M. Lubini5

1Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil, Surgery and Anatomy, Ribeirão Preto, SP, Brazil, 2Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil, 3Universidade Federal de São Paulo (Unifesp), São Paulo, Brazil, 4Clínica Reis Neto, Campinas, SP, Brazil, 5Universidade de Passo Fundo - RG, Passo Fundo / RG, Brazil

P461: Endoscopic features for loss of response in patients with Crohn’s disease who were treated with infliximab by top-down strategy

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Miyazaki*1, K. Watanabe2, K. Kojima1, R. Koshiba1, K. Fujimoto1, T. Sato2, M. Kawai1, K. Kamikozuru1, T. Takagawa1, Y. Yokoyama2, N. Hida1, S. Nakamura1

1Hyogo College of Medicine, Inflammatory Bowel Disease, Nishinomiya, Japan, 2Hyogo College of Medicine, Intestinal Inflammation Research, Nishinomiya, Japan

P462: Dietary restrictions on inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Macedo*1, F. Portela1, A. M. Ferreira1, S. Lopes1, S. Mendes1, M. Ferreira1, L. Tomé1

1Coimbra Hospital and University Centre, Gastroenterology, Coimbra, Portugal

P463: Factors to determine prognosis of intestinal cancer associated with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Shinozaki*1, R. Takahashi1

1The University of Tokyo, Surgery, Tokyo, Japan

P464: Study of the usual aetiologies of methotrexate and azathioprine discontinuation in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Skamnelos*1, K. Katsanos1, D. Christodoulou1

1University Hospital of Ioannina, Division of Gastroenterology, Ioannnina, Greece

P465: UC trial designed more than 5 years ago in the light of the EMA guideline on the development of new medicinal products for the treatment of ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Laoun*1, R. Hofmann2

1Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland, 2Tillotts Pharma, Medical Affairs, Rheinfelden, Switzerland

P466: Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn1, J. Panés*2, R. Panaccione3, G. R. D’Haens4, B. E. Sands5, C. Su6, M. Moscariello6, T. V. Jones6, R. D. Pedersen6, G. S. Friedman6, N. Lawendy6, G. Chan6

1University of California, San Diego, Division of Gastroenterology, La Jolla, CA, USA, 2Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3University of Calgary, Calgary, AB, Canada, 4Academic Medical Centre, Department of Gastroenterology, Amsterdam, The Netherlands, 5Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 6Pfizer Inc., Collegeville, PA, USA

P467: Circulating CD8 α4β7+ and CD8b7+ memory T cells as early biomarkers of clinical response to vedolizumab in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Gonzalez-Vivo1, M. K. Lund Tiirikainen2, C. de Jesús Gi2, E. Ruiz-Romeu2, L. Sans2, L. Canillas1, M. Andreu1, L. F. Santamaria-Babí2, L. Marquez*1

1Hospital del Mar, Gastroenterology, Barcelona, Spain, 2Parc Científic de Barcelona (PCB/UB)., Traslational Immunology, Barcelona, Spain

P468: Long-term function after transanal vs. transabdominal ileal pouch-anal anastomosis for ulcerative colitis: a multi-centre cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Chandrasinghe1, M. Carvello2, K. Wasmann3, P. Tanis3, J. Warusavitarne5, A. Spinelli*2, W. Bemelman3

1Imperial College, London, UK, 2Humanitas Research Hospital, Milan, Italy, 3Academic Medical Center, Amsterdam, The Netherlands, 5St Mark's Hospital, Harrow, UK

P469: Effectiveness of dose optimisation by pre-genotyping NUDT 15 R139C on reducing thiopurine-induced leucopoenia in Chinese patients with Crohn’s disease: a randomised controlled trial

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Chao*1, L. Lin1, Y. Huang2, C. Zhang3, J. Huang1, Q. Cao2, X. Gao1, K. Chao1

1The Sixth Affiliated Hospital, Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China, 2Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China, 3School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China

P470: DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

C. R. Rowan*1, G. Cullen1, H. E. Mulcahy1, J. Sheridan1, A. C. Moss2,3, E. J. Ryan1, G. A. Doherty1

1St.Vincent's University Hospital, Center for Colorectal Disease, Dublin, Ireland, 2Beth Israel Deaconess Medical Center, Gastroenterology, Boston, USA, 3Harvard Medical School, Boston, USA

P471: Association of vedolizumab levels with clinical and biochemical markers of inflammation during maintenance therapy in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Plevris*1, G. R. Jones1, P. W. Jenkinson1, C. S. Chuah1, M. Lyons1, L. M. Merchant1, R. J. Pattenden1, I. D. Arnott1, C. W. Lees1

1Western General Hospital, NHS Lothian, Edinburgh, UK

P472: Efficacy of intravenous ustekinumab re-induction in patients with Crohn’s disease with a loss of response

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Heron*1,2, N. Panaccione3, K. Candido1, T. Bessissow1, A. Bitton1, C. Seow3, R. Panaccione3, W. Afif1

1McGill University Health Centre, Department of Gastroenterology, Montreal, Canada, 2Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada

P473: Cumulative histological inflammation predicts colorectal neoplasia in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

O. V. Yvellez1, V. Rai*1, J. Hart2, J. R. Turner2, K. El Jurdi1, D. T. Rubin1

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, USA, 2Brigham and Women's Hospital, Pathology, Boston, MA, USA

P474: Analysis of UC colectomy rates in pre- and post-biologic era in South-East Scotland

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Jenkinson*1, G. R. Jones1, N. Plevris1, M. Lyons2, K. Kirkwood3, C. Lees1

1Western General Hospital, Gastroenterology, Edinburgh, UK, 2University of Edinburgh, Edinburgh, UK, 3Western General Hospital, Pathology, Edinburgh, UK

P475: Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Facchin*1, A. Buda2, R. Cardin1, R. D'Incà3, F. Zingone3, N. Agbariah1, E. Savarino3

1University of Padua, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, Padova, Italy, 2S.Maria del Prato Hospital,, Department of Oncological Gastrointestinal Surgery, Feltre( BL), Italy, 3University of Padua, Department of Oncological Gastrointestinal Surgery, Padova, Italy

P476: Combined therapy with adalimumab and mesenchymal stromal cells contributes to reduction in the degree of inflammation in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Knyazev1, A. Kagramanova1, D. Kulakov*1, M. Zvyaglova1, A. Parfenov1

1Moscow Clinical Scientific Center named after A. S. Loginov, Department of inflammatory bowel diseases, Moscow, Russian Federation

P477: Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, R. Strauss2, H. Zhang2, J. Johanns2, P. Szapary2, C. Marano2, S. Danese3

1University of California San Diego, La Jolla, USA, 2Janssen Research and Development, LLC, Spring House, USA, 3Humanitas Research Hospital, Milan, Italy

P478: Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Van den Berghe*1, B. Verstockt2,3, S. Tops1, M. Ferrante2,3, S. Vermeire2,3, A. Gils1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P479: Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies

ECCO '19 Copenhagen

Year: 2019
Authors:

G. R. Lichtenstein1, G. T. Moore*2,3, A. Soonasra4, C. I. Nduaka4, K. Kwok5, L. Wang6, N. Lawendy4, G. Chan4, C. Su4, E. V. Loftus Jr.7

1University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, PA, USA, 2Monash Health, Department of Gastroenterology, Melbourne, VIC, Australia, 3Monash University, School of Clinical Sciences at Monash Health, Melbourne, VIC, Australia, 4Pfizer Inc., Collegeville, PA, USA, 5Pfizer Inc., New York, NY, USA, 6Pfizer Inc., Groton, CT, USA, 7Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, MN, USA